⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL596537 | 0.84 | — | — | |
| SCHEMBL597428 | 0.76 | — | — | |
| SCHEMBL2372059 | 0.70 | — | — | |
| SCHEMBL9851980 | 0.67 | — | — | |
| SCHEMBL9169515 | 0.67 | — | — | |
| SCHEMBL6024634 | 0.66 | SOS1 (0.31) | — | |
| SCHEMBL6379784 | 0.66 | — | — | |
| SCHEMBL6582235 | 0.64 | — | — | |
| SCHEMBL597054 | 0.63 | — | — | |
| SCHEMBL3286322 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290322-A | Aromatic molecules for the treatment of pathological conditions | 赛尼欧普罗有限责任公司 | 2024-07-05 | — | — | CN | claimed |
| US-20240140895-A1 | NOVEL AROMATIC MOLECULES | Xeniopro GmbH (DE) | 2024-05-02 | — | — | US | claimed |
| US-20240124489-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-18 | — | — | US | claimed |
| EP-4347597-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-04-10 | — | — | EP | claimed |
| WO-2023233033-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2023-12-07 | — | — | WO | claimed |
| CN-116547282-A | Heterocyclic compounds and their use for the treatment of helminth infections and diseases | 新基公司 | 2023-08-04 | — | — | CN | claimed |
| US-20230141913-A2 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY | Xeniopro GmbH (DE) | 2023-05-11 | — | — | US | claimed |
| WO-2022255408-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-12-08 | — | — | WO | claimed |
| US-20220354949-A1 | NOVEL COMPOUNDS | Xeniopro GmbH (DE) | 2022-11-10 | — | — | US | claimed |
| CN-115124534-A | Non-nucleotide PRMT5 small molecule inhibitor, preparation method and application | 中山大学 | 2022-09-30 | — | — | CN | claimed |
| WO-2007024680-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS | AMGEN INC. (US) | 2007-03-01 | — | — | WO | claimed |
| WO-2006122769-A2 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF DRUGS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | claimed |
| WO-2006121423-A2 | NUCLEIC ACID MELTING ANALYSIS WITH SATURATION DYES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2006-11-16 | — | — | WO | claimed |
| US-20060142269-A1 | New compounds | BIOVITRUM AB (SE) | 2006-06-29 | — | — | US | claimed |
| WO-2006062481-A1 | NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS . | BIOVITRUM AB (SE) | 2006-06-15 | — | — | WO | claimed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | claimed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | claimed |
| EP-1521758-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | Exxonmobil Chemical Patents Inc. (US) | 2005-04-13 | — | — | EP | claimed |
| WO-2004007509-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-01-22 | — | — | WO | claimed |
| US-6498163-B1 | POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-12-24 | — | — | US | claimed |